P0897 - Retrospective Study of the Outcomes of Congestive Heart Failure Exacerbation in Patients With Inflammatory Bowel Disease

Anwar Uddin, MD¹, Nazeera Ghanie, MD², Rafat Uddin, BA¹, Rahat Uddin, MS¹, Madia Ahad, MD¹, Peter Lymberopoulos, MD¹, Aboud Kaliounji, MD³, Prashil Dave, MD³, Nazima Khatun, MD¹, Salman Tajuddin, MD¹, Kian Bagheri, MD¹, Syeda M. Ali, MD¹, Darshan Shantharam, MD¹, Afgal Ahad, MD¹, Sahil Chaddha, MD, MS^1
1SUNY Downstate Medical Center, Brooklyn, NY; ²SUNY Downstate Health Sciences University, Brooklyn, NY; ³State University of New York Downstate, Brooklyn, NY

Introduction: Chronic inflammation is proven to be one of the major risk factors promoting atherosclerosis and thrombosis and inflammatory bowel disease (IBD) is a known risk factor for venous thromboembolism and various ischemic conditions. There is limited data available regarding the congestive heart failure (CHF) outcomes associated with IBD. The aim of present study is to examine the outcomes of CHF exacerbation in patients admitted with IBD

Methods: We used the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) to identify adult patients admitted with IBD during 2016 – 2020 using ICD-10-CM codes (K50 for Crohn's Disease and K51 for Ulcerative Colitis). We divided the patients into two groups based on concomitant diagnosis of CHF exacerbation based on ICD-10-CM codes. Main outcomes were in-hospital mortality, length of stay (LOS), and hospital costs. We evaluate the association between CHF and outcomes using survey based multivariate logistic regression models for in-hospital mortality, Poisson regression for LOS, and generalized linear model with gamma distribution and log link for hospitalization cost. Models were adjusted for age, sex, race and ethnicity, primary payer, Charlson comorbidity index, hospital bed size, hospital region and hospital teaching status.

Results: We identified a total of 1,550,145 IBD hospitalizations between 2016 and 2020 in the United States and 42,015 (2.7%) of them were associated with CHF exacerbation (Table 1). In‐patient mortality was significantly higher in IBD patients with CHF exacerbation (5.9% vs 1.5%, adjusted OR: 4.05, 95%CI: 3.68 – 4.45, P < 0.001, Table 2). IBD patients with CHF exacerbation had an increased length of stay (8.1 ± 0.09 vs 5.3 ± 0.02 days, P < 0.001) and cost of hospitalization ($14,834 ± 87 vs $23,903 ± 423, P < 0.001, Table 2).

Discussion: CHF exacerbations are common in patients with IBD and are associated with higher in‐hospital mortality, increased length of stay, and increased cost of hospitalization.



Disclosures:


Anwar Uddin, MD¹, Nazeera Ghanie, MD², Rafat Uddin, BA¹, Rahat Uddin, MS¹, Madia Ahad, MD¹, Peter Lymberopoulos, MD¹, Aboud Kaliounji, MD³, Prashil Dave, MD³, Nazima Khatun, MD¹, Salman Tajuddin, MD¹, Kian Bagheri, MD¹, Syeda M. Ali, MD¹, Darshan Shantharam, MD¹, Afgal Ahad, MD¹, Sahil Chaddha, MD, MS¹. P0897 - Retrospective Study of the Outcomes of Congestive Heart Failure Exacerbation in Patients With Inflammatory Bowel Disease, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.